Improvement of solubility and oral bioavailability of 2-(N-Cyanoimino)-5- {(E)-4-styrylbenzylidene}-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-β-cyclodextrin

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 3, 2006, Pages 344-349

  Hara, Takumi ^a   Hirayama, Fumitoshi ^a   Arima, Hidetoshi ^a   Yamaguchi, Yoshihiro ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

2 hydroxypropyl cyclodextrin; Bioavailability; Dissolution; FPFS 410; Inclusion complex; Solubility

Indexed keywords

2 (N CYANOIMINO) 5 [(E) 4 STYRYLBENZYLIDENE] 4 OXOTHIAZOLIDINE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; FPFS 410; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHILICITY; HYPERLIPIDEMIA; MALE; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; STOICHIOMETRY; X RAY DIFFRACTION;

ALGORITHMS; ANIMALS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; DOGS; EXCIPIENTS; HYPOGLYCEMIC AGENTS; MALE; MODELS, MOLECULAR; SOLUBILITY; THIAZOLES; X-RAY DIFFRACTION;

EID: 33645238241     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.344     Document Type: Article

References (25)

1. Reaven G. M., Diabetes, 37, 1595-1607 (1988).
2. Lillioja S., Mott D. M., Spraul M., Ferraro R., Foley J. E., Ravussin E., Knowler W. C., Bennett P. H., Bogardus C., N. Eng. J. Med., 329, 1988-1992 (1993).
3. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., Mandarino L. J., Defronzo R. A., J. Clin. Endocrinol. Metab., 87, 2784-2791 (2002).
4. Iozzo P., Hallsten K., Oikonen V., Virtanen K. A., Parkkola R., Kemppainen J., Solin O., Lonnqvist F., Ferrannini E., Knuuti J., Nuutila P., Diabetes Care, 26, 2069-2074 (2003).
5. Aronoff S., Rosenblatt S., Braithwaite S., Egan J. W., Mathisen A. L., Schneider R. L., Diabetes Care, 23, 1605-1611 (2000).
6. Lebovitz H. E., Dole J. F., Patwardhan R., Rappaport E. B., Freed M. I., J. Clin. Endocrinol. Metab., 86, 280-288 (2001).
7. Saltiel A. R., Olefsky J. M., Diabetes, 45, 1661-1669 (1996).
8. Grossman S. L., Lessem J., Expert Opin. Investig. Drugs, 6, 1025-1040 (1997).
9. Ciraldi T. P., Huber-Knudsen K., Hickman M., Olefsky J., Metabolism, 44, 976-982 (1995).
10. Spiegelman B. M., Diabetes, 47, 507-514 (1998).
11. Scheen A. J., Diabetes Metab., 27, 305-313 (2001).
12. Wang C. H., Weisel R. D., Liu P. P., Fedak P. W. M., Verma S., Circulation, 107, 1350-1354 (2003).
13. Norisada N., Masuzaki H., Fujimoto M., Inoue G., Hosoda K., Hayashi T., Watanabe M., Muraoka S., Yoneda F., Nakao K., Metabolism, 53, 1532-1537 (2004).
14. Stella V. J., Rajewski R. A., Pharm. Res., 14, 556-567 (1997).
15. Hirayama F., Uekama K., Adv. Drug Deliv. Rev., 36, 125-141 (1999).
16. Uekama K., Chem. Pharm. Bull., 52, 900-915 (2004).
17. Higuchi T., Connors K. A., Adv. Anal. Chem. Instr., 4, 117-212 (1965).
18. Higuchi T., Kristiansen H., J. Pharm. Sci., 59, 1601-1608 (1970).
19. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmcobio-Dyn., 4, 879-885 (1981).
20. Akaike H., Psychometrika, 52, 317-332 (1987).
21. Miyake K., Irie T., Arima H., Hirayama F., Uekama K., Hirano M., Okamoto Y., Int. J. Pharm., 179, 237-245 (1999).
22. Ikeda Y., Motoune S., Matsuoka T., Arima H., Hirayama F., Uekama K., J. Pharm. Sci., 91, 2390-2398 (2002).
23. Goto J., Kataoka R., Hirayama N., J. Med. Chem., 47, 6804-6811 (2004).
24. Yamaoka K., Nakagawa T., Uno T., J. Pharmacokinet. Biopharm., 6, 547-558 (1978).
25. Shakhtshneider T. P., Boldyrev V. V., Molecular Solid State, 3, 271-311 (1999).